This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...
Peter Cackett spoke to ophthalmologist and social media sensation Dr Glaucomflecken about his early days in comedy, the role satire can play in impacting medical governance, and where he might take his brand of medical comedy next. It was towards...
A machine might be called intelligent if its response to questions could convince a person that it was human, a test proposed by Alan Turing in 1950 [1]. The author considers potential applications of artificial intelligence (AI) using machine learning...
See also - See sweet to C-suite: Peter Holland In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part Two: David speaks...
CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...
This is a single centre prospective study for the long-term, whole population ‘real-world’ clinical outcomes of ranibizumab therapy in treatment-naïve patients for neovascular age-related macular degeneration (AMD). This study recorded: demographics, Early Treatment Diabetic Retinopathy Study visual acuity (ETDRS VA)...
In this prospective study the authors evaluate the effect of intravitreal aflibercept injections in the treatment of naive type 3 neovascularisation using a fixed treatment regime. Fourteen eyes of 14 patients were studied. All patients were treated with intravitreal 2.0...
Half-dose photodynamic therapy (HD-PDT) with verteporfin has been the therapy of choice in non-resolving central serous chorioretinopathy lasting longer than four months. Since 2021, a worldwide shortage of verteporfin due to manufacturing issues prompted adjustments in treatment practices. This retrospective,...
*Please be aware that this data does not form part of a peer reviewed research study. The information therein should not be relied upon for clinical purposes but instead used as a guide for clinical practice and reflection. I continue...
In the hustle and bustle of ¡Hola! (Hello) and ¿Cómo estás? (How are you?), a group of travellers from different parts of UK went on a Mexican adventure to explore the diverse culture of Mexico, diving straight into the turquoise...
Prostaglandins are known to cause periorbital adverse effects. The aim of this retrospective case series was to compare the frequency of prostaglandin associated periorbitopathy (PAP) between bimatoprost, latanoprost and travoprost users. Five PAP findings were evaluated: upper lid ptosis, deepening...